Galderma, a Swiss pharmaceutical company with a strong reputation for its skin care treatments, is seizing an opportunity in the “Ozempic face” phenomenon. The CEO believes that the growing popularity of weight-loss drugs like Ozempic could lead to increased demand for their facial fillers products. This is because Ozempic can cause a sunken-in look in some patients’ faces, which fillers can help counteract.
Galderma has been developing products to address this issue, including Sculptra, which is designed to restore the gaunt look associated with Ozempic face. The company has also started a study to evaluate the effects of Sculptra and Restylane for cheek augmentation and contour deficiencies in patients using GLP-1 treatments. Enrollment is ongoing, and results may be available by the end of the year.
Dermatologists have observed that “Ozempic face” has become increasingly common in their practices due to the widespread use of weight-loss medications. The term refers to the sunken and aged appearance that can result from rapid weight loss.
Galderma reported a 12.4% increase in sales year-over-year in the first quarter of this year, while also owning popular drug store brand Cetaphil. The CEO remains optimistic about the growth potential in the fillers market and plans to capitalize on the trend of weight-loss drugs like Ozempic as they become more popular among patients seeking cosmetic solutions for their rapid weight loss.
The study conducted by Galderma aims to provide valuable insights into how these treatments can be used effectively and safely in patients using GLP-1 treatments. This will not only benefit patients but also help dermatologists make informed decisions when treating their patients who are experiencing Ozempic face.
In conclusion, Galderma’s decision to capitalize on the “Ozempic face” phenomenon shows their commitment to innovation and providing solutions for their customers’ needs. As more people turn to weight-loss medications like Ozempic, it’s important for companies like Galderma to offer products that address any negative side effects or consequences that may arise from these treatments.